Cargando…

Warfarin and Antibiotics: Drug Interactions and Clinical Considerations

Warfarin administration poses a notable challenge in clinical practice due to the increased susceptibility of patients to major bleeding, particularly when co-administered with other medications capable of modulating its metabolic pathways. Among these medications, antibiotics have been recognized a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vega, Alexis J., Smith, Caitlin, Matejowsky, Hannah Grace, Thornhill, Katherine J., Borne, Grant E., Mosieri, Chizoba N., Shekoohi, Sahar, Cornett, Elyse M., Kaye, Alan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455514/
https://www.ncbi.nlm.nih.gov/pubmed/37629518
http://dx.doi.org/10.3390/life13081661
_version_ 1785096470497591296
author Vega, Alexis J.
Smith, Caitlin
Matejowsky, Hannah Grace
Thornhill, Katherine J.
Borne, Grant E.
Mosieri, Chizoba N.
Shekoohi, Sahar
Cornett, Elyse M.
Kaye, Alan D.
author_facet Vega, Alexis J.
Smith, Caitlin
Matejowsky, Hannah Grace
Thornhill, Katherine J.
Borne, Grant E.
Mosieri, Chizoba N.
Shekoohi, Sahar
Cornett, Elyse M.
Kaye, Alan D.
author_sort Vega, Alexis J.
collection PubMed
description Warfarin administration poses a notable challenge in clinical practice due to the increased susceptibility of patients to major bleeding, particularly when co-administered with other medications capable of modulating its metabolic pathways. Among these medications, antibiotics have been recognized as potential agents that can either induce or inhibit cytochrome P450-2C9, thereby impacting the effects of warfarin. A wealth of evidence from numerous studies consistently supports an elevated risk of serious bleeding in patients concurrently receiving antibiotics and warfarin therapy. This narrative review elucidates the intricate interactions between warfarin and various antibiotic classes. Notably, significant increases in the International Normalized Ratio (INR) were observed among warfarin-treated patients receiving penicillin derivatives, fluoroquinolones, TMP-SMX, and macrolides. Conversely, investigations have also demonstrated a reduction in INR levels in patients on warfarin when exposed to rifampin, a potent inducer of cytochrome P-450. Intriguingly, cephalosporin antibiotics and amoxicillin/clavulanate, despite not interfering with the cytochrome P450 system, exhibited a positive association with increased INR values. The findings of this narrative review underscore the importance of diligent monitoring in patients on warfarin requiring concomitant antibiotic therapy, as this surveillance strategy proves pivotal in mitigating the risk of major bleeding complications. Additionally, for patients necessitating cytochrome P450 inhibitors such as penicillin derivatives, fluoroquinolones, TMP-SMX, and macrolides, the consideration of dose reduction in warfarin therapy may confer substantial benefits in reducing the occurrence of major bleeding events. Similarly, patients who are co-administered rifampin alongside warfarin necessitate vigilant monitoring, with a potential need for escalating warfarin doses to counteract the risk of a hypercoagulable state.
format Online
Article
Text
id pubmed-10455514
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104555142023-08-26 Warfarin and Antibiotics: Drug Interactions and Clinical Considerations Vega, Alexis J. Smith, Caitlin Matejowsky, Hannah Grace Thornhill, Katherine J. Borne, Grant E. Mosieri, Chizoba N. Shekoohi, Sahar Cornett, Elyse M. Kaye, Alan D. Life (Basel) Review Warfarin administration poses a notable challenge in clinical practice due to the increased susceptibility of patients to major bleeding, particularly when co-administered with other medications capable of modulating its metabolic pathways. Among these medications, antibiotics have been recognized as potential agents that can either induce or inhibit cytochrome P450-2C9, thereby impacting the effects of warfarin. A wealth of evidence from numerous studies consistently supports an elevated risk of serious bleeding in patients concurrently receiving antibiotics and warfarin therapy. This narrative review elucidates the intricate interactions between warfarin and various antibiotic classes. Notably, significant increases in the International Normalized Ratio (INR) were observed among warfarin-treated patients receiving penicillin derivatives, fluoroquinolones, TMP-SMX, and macrolides. Conversely, investigations have also demonstrated a reduction in INR levels in patients on warfarin when exposed to rifampin, a potent inducer of cytochrome P-450. Intriguingly, cephalosporin antibiotics and amoxicillin/clavulanate, despite not interfering with the cytochrome P450 system, exhibited a positive association with increased INR values. The findings of this narrative review underscore the importance of diligent monitoring in patients on warfarin requiring concomitant antibiotic therapy, as this surveillance strategy proves pivotal in mitigating the risk of major bleeding complications. Additionally, for patients necessitating cytochrome P450 inhibitors such as penicillin derivatives, fluoroquinolones, TMP-SMX, and macrolides, the consideration of dose reduction in warfarin therapy may confer substantial benefits in reducing the occurrence of major bleeding events. Similarly, patients who are co-administered rifampin alongside warfarin necessitate vigilant monitoring, with a potential need for escalating warfarin doses to counteract the risk of a hypercoagulable state. MDPI 2023-07-30 /pmc/articles/PMC10455514/ /pubmed/37629518 http://dx.doi.org/10.3390/life13081661 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vega, Alexis J.
Smith, Caitlin
Matejowsky, Hannah Grace
Thornhill, Katherine J.
Borne, Grant E.
Mosieri, Chizoba N.
Shekoohi, Sahar
Cornett, Elyse M.
Kaye, Alan D.
Warfarin and Antibiotics: Drug Interactions and Clinical Considerations
title Warfarin and Antibiotics: Drug Interactions and Clinical Considerations
title_full Warfarin and Antibiotics: Drug Interactions and Clinical Considerations
title_fullStr Warfarin and Antibiotics: Drug Interactions and Clinical Considerations
title_full_unstemmed Warfarin and Antibiotics: Drug Interactions and Clinical Considerations
title_short Warfarin and Antibiotics: Drug Interactions and Clinical Considerations
title_sort warfarin and antibiotics: drug interactions and clinical considerations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455514/
https://www.ncbi.nlm.nih.gov/pubmed/37629518
http://dx.doi.org/10.3390/life13081661
work_keys_str_mv AT vegaalexisj warfarinandantibioticsdruginteractionsandclinicalconsiderations
AT smithcaitlin warfarinandantibioticsdruginteractionsandclinicalconsiderations
AT matejowskyhannahgrace warfarinandantibioticsdruginteractionsandclinicalconsiderations
AT thornhillkatherinej warfarinandantibioticsdruginteractionsandclinicalconsiderations
AT bornegrante warfarinandantibioticsdruginteractionsandclinicalconsiderations
AT mosierichizoban warfarinandantibioticsdruginteractionsandclinicalconsiderations
AT shekoohisahar warfarinandantibioticsdruginteractionsandclinicalconsiderations
AT cornettelysem warfarinandantibioticsdruginteractionsandclinicalconsiderations
AT kayealand warfarinandantibioticsdruginteractionsandclinicalconsiderations